Company Overview
Founded and officially operated since 2021, ChomiX Biotech Co., Ltd is a pioneering biotechnology company dedicated to the preclinical R&D of innovative small molecule drugs. Leveraging cutting-edge chemoproteomics as our core technology, we specialize in the novel lead compound screening and the discovery of new targets for active drug molecules within living cell systems.
ChomiX has formed partnerships with dozens of small molecule drug R&D companies as well as with hundreds of research groups from leading universities and hospitals, such as Peking University, Nanjing University, Sun Yat-sen University, and China Pharmaceutical University. We are committed to rapidly breaking through the undruggable barriers of disease targets and accelerating the discovery of new drugs.
Core Team
Inspired by Leaders: Our Distinguished Core Members
Dr. Nan Chen
Founder & CEO
Dr. Nan Chen completed his PhD in 2019 at Peking University, where he conducted research under the supervision of Professor Chu Wang. He then pursued postdoctoral research with Professor Tarun Kapoor at the Rockefeller University.
Dr. FengYing Zhang
Sr. R&D Director
Dr. FengYing Zhang completed his Ph.D in Medicinal Chemistry in 2013 at Peking University. Now, he responsible for the preclinical R&D of the drug pipeline
Scientific Consultant Team
If we have seen further, it is by standing on the shoulders of giants
Prof. Chu Wang
CSO
Prof. Jin Zhao
Professor, Nanjing University
Prof. Ran Xie
Professor, Nanjing University
Prof. ZiJian Guo
Academician, Nanjing University
Prof. Jie Li
Professor, Nanjing University